Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Dynavax Technologies is a biopharmaceutical company specializing in developing and commercializing innovative vaccines. Its core product, HEPLISAV-B, is a two-dose hepatitis B vaccine utilizing proprietary CpG 1018 adjuvant technology. The company focuses on vaccines for infectious diseases, leveraging its adjuvant platform to enhance immune responses. It targets adult markets globally, emphasizing vaccine innovation, pipeline expansion, and strategic collaborations to address unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.